ロード中...
FLT3 inhibitors in acute myeloid leukemia
FLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclini...
保存先:
| 出版年: | J Hematol Oncol |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6280371/ https://ncbi.nlm.nih.gov/pubmed/30514344 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-018-0675-4 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|